Lv3
270 积分 2022-08-31 加入
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
2小时前
已完结
A Phase II Clinical Study on Apatinib Plus Vinorelbine in Refractory HER2-Negative Breast Cancer and its Metabolic Implications of Drug Resistance
2小时前
已完结
Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1
12天前
已完结
A network meta-analysis of direct factor Xa inhibitors for the treatment of cancer-associated venous thromboembolism
19天前
已完结
Real-world comparative effectiveness of dalteparin and enoxaparin for venous thromboembolism prophylaxis
19天前
已完结
Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism
19天前
已完结
Pharmacology of Heparin and Related Drugs: An Update
19天前
已完结
Heparin: An old drug for new clinical applications
19天前
已完结
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
3个月前
已完结
Prediction of biochemical nonresolution in patients with chronic drug‐induced liver injury: A large multicenter study
6个月前
已完结
皖公网安备34019202002308
